BaglinT. Inherited and acquired risk factors for venous thromboembolism. Semin Respir Crit Care Med. 2012;33(2):127–137.
2.
NikolaouVSDesyNMBergeronSGAntoniouJ. Total knee replacement and chemical thromboprophylaxis: current evidence. Curr Vasc Pharmacol. 2011;9(1):33–41.
3.
Gomez-OutesALecumberriRPozoCRochaE. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol. 2009;7(3):309–329.
4.
ParaskevasKIStathopoulosVMikhailidisDP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008;6(4):237–239.
5.
OlivieriFMazzantiIAbbatecolaAM. Telomere/Telomerase system: a new target of statins pleiotropic effect?Curr Vasc Pharmacol. 2012;10(2):216–224.
6.
ParaskevasKIMikhailidisDPRoussasNGiannoukasAD. Effect of antiplatelet agents, statins, and other drugs on vascular access patency rates. Angiology. 2012;63(1):5–8.
7.
TziomalosKAthyrosVGKaragiannisAMikhailidisDP. Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol. 2012;10(1):33–41.
8.
IakovisPAnyfantakisZALimasCKroupisCDegiannisDCokkinosDV. Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: effects of statin therapy. Angiology. 2011;62(1):55–61.
9.
RayJGMamdaniMTsuyukiRTAndersonDRYeoELLaupacisA. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161(11):1405–1410.
10.
GradyDWengerNKHerringtonD. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132(9):689–696.
11.
HerringtonDMVittinghoffELinF. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002;105(25):2962–2967.
12.
DoggenCJLemaitreRNSmithNLHeckbertSRPsatyBM. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost. 2004;2(5):700–701.
13.
LacutKOgerELe GalG. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol. 2004;18(4):477–482.
14.
RamcharanASVan StralenKJSnoepKJMantel-TeeuwisseAKRosendaalFRDoggenCJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy and the risk of venous thrombosis. J Thromb Haemost. 2009;7(4):514–520.
15.
ParaskevasKIBessiasNPerdikidesTPMikhailidisDP. Statins and venous thromboembolism: a novel effect of statins?Curr Med Res Opin. 2009;25(7):1807–1809.
16.
GlynnRJDanielsonEFonsecaFA. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–1861.
17.
SquizzatoAGalliMRomualdiE. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J. 2010;31(10):1248–1256.
18.
RahimiKBhalaNKamphuisenP. Effect of statins and venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med. 2012;9(9):e1001310.
19.
KhemasuwanDChaeYKGuptaS. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med. 2011;124(9):852–859.
20.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
21.
AmarencoPBogousslavskyJCallahanA 3rd; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559.
22.
FreemanDJRobertsonMBrownEA. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatr. 2011;11:8.
23.
Rosendaal FR. Statins and venous thrombosis: a story too good to be true?PLoS Med. 2012;9(9):e1001311.
24.
RabinowichLSteinvilALeshem-RubinowE. Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation [published online October 4, 2012]. Heart. 2012.
25.
TziomalosKAthyrosVGMikhailidisDP. Statin discontinuation: an underestimated risk?Curr Med Res Opin. 2008;24(11):3059–3062.
26.
BennerJSGlynnRJMogunHNeumannPJWeinsteinMCAvornJ. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–461.
27.
RosenbaumDDallongevilleJSabouretPBruckertE. Discontinuation of statin therapy due to muscular side effects: a survey in real life [published online June 28, 2012]. Nutr Metab Cardiovasc Dis. 2012.
28.
WhayneTF Jr. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators. Angiology. 2011;62(5):415–421.
29.
CatapanoAL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol. 2012;10(2):257–267.
30.
TziomalosKAthyrosVGKaragiannisAMikhailidisDP. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol. 2010;8(5):632–637.
31.
GaziIFDaskalopoulouSSNairDRMikhailidisDP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007;23(9):2183–2192.
